Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).
Marc Peeters, MD, PhD
Advertisement
Articles by Marc Peeters, MD, PhD
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.
Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Peeters on the Utility of Aflibercept in CRCPublished: October 22nd 2013 | Updated:
- Dr. Peeters on KRAS/NRAS Mutations in mCRC
Published: February 6th 2014 | Updated:
Dr. Peeters on the Future of Colorectal CancerPublished: March 11th 2014 | Updated:
Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRCPublished: August 19th 2014 | Updated:
Dr. Marc Peeters on the Aflibercept Toxicity ProfilePublished: July 9th 2013 | Updated:
Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRCPublished: June 27th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5